Clinical trials

Below are current clinical trials.


2 studies in Monoclonal gammopathy of undetermined significance (MGUS)
(open studies only).

Filter this list of studies by location, status and more.

April 27, 2016
References
  1. Rajkumar SV. Diagnosis of monoclonal gammopathy of undetermined significance. http://www.uptodate.com/home. Accessed Feb. 17, 2016.
  2. Rajkumar SV. Clinical course and management of monoclonal gammopathy of undetermined significance. http://www.uptodate.com/home. Accessed Feb. 17, 2016.
  3. Ferri FF. Monoclonal gammopathy of undetermined significance (MGUS). In: Ferri's Clinical Advisor 2016. Philadelphia, Pa.: Mosby Elsevier; 2016. https://www.clinicalkey.com. Accessed Feb. 17, 2016.
  4. Glavey SV, et al. Monoclonal gammopathy: The good, the bad and the ugly. Blood Reviews. In press. http://dx.doi.org/10.1016/j.blre.2015.12.001. Accessed Feb. 18, 2016.
  5. Goldman L, et al., eds. Plasma cell disorders. In: Goldman-Cecil Medicine. 25th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. http://www.clinicalkey.com. Accessed Feb. 11, 2016.
  6. AskMayoExpert. Monoclonal gammopathy of undetermined significance (MGUS) prevalence. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
  7. Kyle RA, et al. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematology/Oncology Clinics of North America. 2014;28:775.
  8. Sethi S, et al. Spectrum of manifestations of monoclonal gammopathy-associated renal syndromes. Current Opinion in Nephrology and Hypertension. 2016;25:127.
  9. AskMayoExpert. Monoclonal gammopathy of undetermined significance (MGUS). Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
  10. Riggin EA. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Jan. 13, 2016.